| Bioactivity | DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits PI3K/Akt/mTOR pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC50s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice[1]. |
| CAS | 2125500-60-7 |
| Formula | C26H26F2N6O5S |
| Molar Mass | 572.58 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fan Y, et al., Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer. Cancers (Basel). 2019 May 5;11(5):627. |
DFX117
CAS: 2125500-60-7 F: C26H26F2N6O5S W: 572.58
DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits PI3K/Akt/mTOR pathw
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.